Event Description
What does it take to end an infectious disease for good? Join us to explore the difference between eradication and elimination, the criteria diseases must meet to qualify, and the critical role of disease surveillance in preventing outbreaks. We’ll also show why investments from high-income countries in global vaccination efforts protect us all—locally and globally.
Upon successful completion of this course, learners should be able to:
- Define eradication and elimination and the criteria required for making a disease eligible for eradication.
- Describe why disease surveillance, including whether cases are the result of vaccine failure or failure to vaccinate, plays a critical role in disease eradication and elimination.
- Explain how investments by high income countries to support efforts to eradicate or eliminate vaccine-preventable diseases in low income countries benefit both low and high income countries.
About the Speaker
Walter A. Orenstein, MD, is Professor Emeritus in the Emory School of Medicine. He was a former Professor of Medicine, Epidemiology, Global Health, and Pediatrics at Emory University; as well as the Associate Director of the Emory Vaccine Center and Director of the Emory Program on Vaccine Policy and Development. He has formerly served as Deputy Director for Immunization Programs at the Bill & Melinda Gates Foundation where he focused on polio eradication, measles control, and improving routine immunization programs. He has also served as Director of the United States Immunization Program at the Centers for Disease Control and Prevention (CDC), Assistant Surgeon General of the United States Public Health Service (USPHS), and President of the National Foundation for Infectious Diseases (NFID).
Dr. Orenstein is a past Chair of the World Health Organization (WHO) Poliomyelitis Technical Consultative Group and served as the Chair of the National Vaccine Advisory Committee (NVAC). He is also currently a member of the WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization Polio as well as Measles and Rubella Working Groups.
Dr. Orenstein’s research focus has been on assessment of vaccine effectiveness in observational studies, methods to overcome vaccine hesitancy, ways to enhance uptake of recommended vaccines, and ways to facilitate polio eradication and sustain that eradication.
Continuing Education
Instructions for claiming continuing education credit are provided during the webinar.
For questions regarding continuing education, please email cire.cme@ndsu.edu.
Continuing Medical Education (CME)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Minnesota Medical Association and NDSU. The Minnesota Medical Association (MMA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Minnesota Medical Association designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education (CPE)
This activity is approved for 0.1 CEU of pharmacist and pharmacy technician credit by CEImpact. CEimpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
More information is available via the NDSU CAP Center.
